Arnatar Therapeutics
@arnatarthera.bsky.social
We are a biotechnology company pioneering RNA-based therapeutics to address high unmet medical needs in cardiovascular, metabolic, CNS, liver, and kidney diseases.
Alagille syndrome (ALGS) is caused by 𝘑𝘈𝘎1 haploinsufficiency, leading to reduced Jagged1 protein and impairment of bile ducts.
Arnatar’s ART4, an upregulating ASO for 𝘑𝘈𝘎1, restores Jagged1 and liver function in ALGS models—now advancing in humans.
Learn more: arnatar.com/pipeline
Arnatar’s ART4, an upregulating ASO for 𝘑𝘈𝘎1, restores Jagged1 and liver function in ALGS models—now advancing in humans.
Learn more: arnatar.com/pipeline
November 5, 2025 at 4:25 PM
Alagille syndrome (ALGS) is caused by 𝘑𝘈𝘎1 haploinsufficiency, leading to reduced Jagged1 protein and impairment of bile ducts.
Arnatar’s ART4, an upregulating ASO for 𝘑𝘈𝘎1, restores Jagged1 and liver function in ALGS models—now advancing in humans.
Learn more: arnatar.com/pipeline
Arnatar’s ART4, an upregulating ASO for 𝘑𝘈𝘎1, restores Jagged1 and liver function in ALGS models—now advancing in humans.
Learn more: arnatar.com/pipeline
At Arnatar, we’re pioneering next-gen #RNAMedicines to treat severe & underserved diseases. Backed by our DARGER™ Platform, we advance antisense & #siRNA therapeutics that both up and down-regulate gene expression with precision.
Explore our pipeline: https://www.arnatar.com/pipeline
Explore our pipeline: https://www.arnatar.com/pipeline
September 17, 2025 at 9:01 PM
At Arnatar, we’re pioneering next-gen #RNAMedicines to treat severe & underserved diseases. Backed by our DARGER™ Platform, we advance antisense & #siRNA therapeutics that both up and down-regulate gene expression with precision.
Explore our pipeline: https://www.arnatar.com/pipeline
Explore our pipeline: https://www.arnatar.com/pipeline